OHR Pharmaceutical Stock Price, News & Analysis (NASDAQ:OHRP)

$0.27 0.00 (0.00 %)
(As of 02/20/2018 10:43 AM ET)
Previous Close$0.27
Today's Range$0.27 - $0.28
52-Week Range$0.26 - $2.18
Volume1.26 million shs
Average Volume3.89 million shs
Market Capitalization$15.09 million
P/E Ratio-0.62
Dividend YieldN/A
Beta-0.18

About OHR Pharmaceutical (NASDAQ:OHRP)

OHR Pharmaceutical logoOHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, proliferative diabetic retinopathy, and retinal vein occlusion. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as glaucoma, steroid induced glaucoma, ocular allergy, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.

Receive OHRP News and Ratings via Email

Sign-up to receive the latest news and ratings for OHRP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OHRP
CUSIPN/A
Phone212-682-8452

Debt

Debt-to-Equity RatioN/A
Current Ratio2.46%
Quick Ratio2.46%

Price-To-Earnings

Trailing P/E Ratio-0.61649729076068
Forward P/E RatioInfinity
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.41 per share
Price / Book0.66

Profitability

Trailing EPS($0.43)
Net Income$-23,810,000.00
Net MarginsN/A
Return on Equity-94.42%
Return on Assets-75.99%

Miscellaneous

Employees4
Outstanding Shares56,470,000

OHR Pharmaceutical (NASDAQ:OHRP) Frequently Asked Questions

What is OHR Pharmaceutical's stock symbol?

OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP."

How were OHR Pharmaceutical's earnings last quarter?

OHR Pharmaceutical Inc (NASDAQ:OHRP) announced its quarterly earnings data on Friday, December, 15th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.08). View OHR Pharmaceutical's Earnings History.

Where is OHR Pharmaceutical's stock going? Where will OHR Pharmaceutical's stock price be in 2018?

2 analysts have issued 12-month price targets for OHR Pharmaceutical's stock. Their forecasts range from $7.00 to $10.00. On average, they anticipate OHR Pharmaceutical's share price to reach $8.50 in the next twelve months. View Analyst Ratings for OHR Pharmaceutical.

Are investors shorting OHR Pharmaceutical?

OHR Pharmaceutical saw a increase in short interest in the month of January. As of January 12th, there was short interest totalling 3,075,035 shares, an increase of 47.8% from the December 29th total of 2,080,161 shares. Based on an average daily volume of 7,535,665 shares, the short-interest ratio is currently 0.4 days. Currently, 5.7% of the shares of the company are sold short.

Who are some of OHR Pharmaceutical's key competitors?

Who are OHR Pharmaceutical's key executives?

OHR Pharmaceutical's management team includes the folowing people:

  • Michael A. Ferguson, Chairman of the Board
  • Jason Scott Slakter M.D., Chief Executive Officer, Director (Age 58)
  • Sam Backenroth, Chief Financial Officer, Vice President - Business Development (Age 31)
  • Avner Ingerman M.D., Chief Clinical Officer (Age 52)
  • June S. Almenoff M.D. Ph.D., Independent Director (Age 60)
  • Orin Hirschman, Independent Director (Age 47)
  • Thomas M. Riedhammer Ph.D., Independent Director (Age 68)

Who owns OHR Pharmaceutical stock?

OHR Pharmaceutical's stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (1.87%) and Wedbush Securities Inc. (1.18%). Company insiders that own OHR Pharmaceutical stock include Jason Scott Slakter, Orin Hirschman and Samuel Backenroth. View Institutional Ownership Trends for OHR Pharmaceutical.

Who bought OHR Pharmaceutical stock? Who is buying OHR Pharmaceutical stock?

OHR Pharmaceutical's stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Wedbush Securities Inc.. Company insiders that have bought OHR Pharmaceutical stock in the last two years include Jason Scott Slakter, Orin Hirschman and Samuel Backenroth. View Insider Buying and Selling for OHR Pharmaceutical.

How do I buy OHR Pharmaceutical stock?

Shares of OHR Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OHR Pharmaceutical's stock price today?

One share of OHR Pharmaceutical stock can currently be purchased for approximately $0.27.

How big of a company is OHR Pharmaceutical?

OHR Pharmaceutical has a market capitalization of $15.09 million. The biotechnology company earns $-23,810,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis. OHR Pharmaceutical employs 4 workers across the globe.

How can I contact OHR Pharmaceutical?

OHR Pharmaceutical's mailing address is 800 THIRD AVENUE 11TH FLOOR, NEW YORK NY, 10022. The biotechnology company can be reached via phone at 212-682-8452 or via email at [email protected]


MarketBeat Community Rating for OHR Pharmaceutical (OHRP)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  178 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  297
MarketBeat's community ratings are surveys of what our community members think about OHR Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

OHR Pharmaceutical (NASDAQ:OHRP) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.503.002.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.50$8.50$10.00$10.00
Price Target Upside: 320.79% upside320.79% upside1,539.34% upside1,539.34% upside

OHR Pharmaceutical (NASDAQ:OHRP) Consensus Price Target History

Price Target History for OHR Pharmaceutical (NASDAQ:OHRP)

OHR Pharmaceutical (NASDAQ:OHRP) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/5/2018Roth CapitalDowngradeBuy -> Neutral$7.00HighView Rating Details
8/16/2017HC WainwrightSet Price TargetBuy$10.00HighView Rating Details
10/4/2016Brean CapitalInitiated CoverageHoldN/AView Rating Details
5/16/2016Chardan CapitalReiterated RatingHoldN/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

OHR Pharmaceutical (NASDAQ:OHRP) Earnings History and Estimates Chart

Earnings by Quarter for OHR Pharmaceutical (NASDAQ:OHRP)

OHR Pharmaceutical (NASDAQ OHRP) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/15/2018Q1 2018($0.07)($0.07)ViewN/AView Earnings Details
12/15/2017Q4 2017($0.08)($0.08)ViewN/AView Earnings Details
8/8/2017Q3 2017($0.25)($0.07)ViewListenView Earnings Details
5/11/2017Q2 2017($0.30)($0.21)ViewN/AView Earnings Details
2/14/2017Q117($0.19)($0.21)ViewListenView Earnings Details
12/22/2016Q4 2016($0.24)($0.21)ViewN/AView Earnings Details
8/9/2016Q3 2016($0.23)($0.24)ViewN/AView Earnings Details
5/10/2016Q2($0.18)($0.17)ViewListenView Earnings Details
2/9/2016Q1 2016($0.24)($0.20)ViewN/AView Earnings Details
12/10/2015Q415($0.20)($0.13)ViewListenView Earnings Details
8/6/2015Q3 2015($0.21)($0.11)ViewN/AView Earnings Details
5/11/2015Q215($0.17)($0.12)ViewListenView Earnings Details
2/9/2015Q115($0.20)($0.18)ViewN/AView Earnings Details
12/22/2014($0.10)($0.12)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

OHR Pharmaceutical (NASDAQ:OHRP) Earnings Estimates

Next Year EPS Consensus Estimate: $-0.81 EPS

Dividends

Dividend History for OHR Pharmaceutical (NASDAQ:OHRP)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

OHR Pharmaceutical (NASDAQ OHRP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 9.52%
Insider Trades by Quarter for OHR Pharmaceutical (NASDAQ:OHRP)
Institutional Ownership by Quarter for OHR Pharmaceutical (NASDAQ:OHRP)

OHR Pharmaceutical (NASDAQ OHRP) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/10/2017Orin HirschmanDirectorBuy142,858$0.70$100,000.60View SEC Filing  
4/10/2017Samuel BackenrothCFOBuy71,429$0.70$50,000.30212,596View SEC Filing  
6/20/2016Jason Scott SlakterCEOBuy8,786$2.85$25,040.10917,954View SEC Filing  
6/20/2016Samuel BackenrothCFOBuy2,468$2.84$7,009.12138,709View SEC Filing  
5/25/2016Jason Scott SlakterCEOBuy3,682$3.11$11,451.02913,072View SEC Filing  
5/24/2016Jason Scott SlakterCEOBuy28,068$3.15$88,414.20885,841View SEC Filing  
5/23/2016Samuel BackenrothCFOBuy2,500$3.17$7,925.00136,362View SEC Filing  
4/11/2016Jason Scott SlakterCEOBuy6,250$3.35$20,937.50884,504View SEC Filing  
3/7/2016Jason Scott SlakterCEOBuy6,250$3.63$22,687.50873,527View SEC Filing  
2/22/2016Jason Scott SlakterCEOBuy6,250$3.11$19,437.50865,854View SEC Filing  
1/19/2016Jason Scott SlakterCEOBuy6,250$3.62$22,625.00865,754View SEC Filing  
12/7/2015Jason Scott SlakterCEOBuy3,000$4.07$12,210.00509,146View SEC Filing  
11/3/2015Jason Scott SlakterCEOBuy13,350$3.00$40,050.0077,923View SEC Filing  
2/6/2015Irach B TaraporewalaCEOBuy3,705$6.75$25,008.75View SEC Filing  
2/6/2015June Sherie AlmenoffDirectorBuy6,000$6.75$40,500.00View SEC Filing  
2/6/2015Samuel BackenrothCFOBuy1,500$6.75$10,125.00View SEC Filing  
9/3/2014June Sherie AlmenoffDirectorBuy2,200$8.08$17,776.00View SEC Filing  
7/2/2014Ira A GreensteinDirectorBuy1,000$8.40$8,400.00View SEC Filing  
6/26/2014June Sherie AlmenoffDirectorBuy3,200$8.34$26,688.00View SEC Filing  
6/25/2014Thomas M RiedhammerDirectorBuy6,900$7.39$50,991.00View SEC Filing  
4/9/2014Ira A GreensteinDirectorBuy2,500$10.20$25,500.00View SEC Filing  
4/8/2014June Sherie AlmenoffDirectorBuy5,500$10.25$56,375.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

OHR Pharmaceutical (NASDAQ OHRP) News Headlines

Source:
DateHeadline
Robbins Arroyo LLP: Ohr Pharmaceutical, Inc. (OHRP) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)Robbins Arroyo LLP: Ohr Pharmaceutical, Inc. (OHRP) Misled Shareholders According to a Recently Filed Class Action - Business Wire (press release)
www.businesswire.com - February 18 at 8:14 AM
Robbins Arroyo LLP: Ohr Pharmaceutical, Inc. (OHRP) Misled Shareholders According to a Recently Filed Class ActionRobbins Arroyo LLP: Ohr Pharmaceutical, Inc. (OHRP) Misled Shareholders According to a Recently Filed Class Action
finance.yahoo.com - February 17 at 8:11 AM
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Ohr Pharmaceutical, Inc.Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Ohr Pharmaceutical, Inc.
finance.yahoo.com - February 15 at 5:23 PM
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) To Contact Brower Piven Before The Lead Plaintiff DeadlineSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Ohr Pharmaceutical, Inc. (Nasdaq: OHRP) To Contact Brower Piven Before The Lead Plaintiff Deadline
finance.yahoo.com - February 15 at 5:23 PM
OHRP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ohr Pharmaceutical, Inc.OHRP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Ohr Pharmaceutical, Inc.
finance.yahoo.com - February 15 at 5:23 PM
OHR Pharmaceutical (OHRP) Announces  Earnings Results, Meets EstimatesOHR Pharmaceutical (OHRP) Announces Earnings Results, Meets Estimates
www.americanbankingnews.com - February 15 at 10:08 AM
Ohr Pharmaceutical Reports Fiscal First Quarter 2018 Financial ResultsOhr Pharmaceutical Reports Fiscal First Quarter 2018 Financial Results
finance.yahoo.com - February 15 at 9:25 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018 -- OHRPSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Ohr Pharmaceutical, Inc. Investors and Sets a Lead Plaintiff Deadline of April 16, 2018 -- OHRP
finance.yahoo.com - February 14 at 3:43 PM
Who Are The Major Shareholders Of OHR Pharmaceutical Inc (NASDAQ:OHRP)?Who Are The Major Shareholders Of OHR Pharmaceutical Inc (NASDAQ:OHRP)?
finance.yahoo.com - February 12 at 9:18 AM
OHR Pharmaceutical (OHRP) Scheduled to Post Quarterly Earnings on MondayOHR Pharmaceutical (OHRP) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - February 5 at 4:16 AM
OHR Pharmaceutical (OHRP) Stock Rating Upgraded by ValuEngineOHR Pharmaceutical (OHRP) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - February 4 at 7:10 PM
OHR Pharmaceutical Inc (OHRP) Short Interest Up 47.8% in JanuaryOHR Pharmaceutical Inc (OHRP) Short Interest Up 47.8% in January
www.americanbankingnews.com - January 28 at 1:08 AM
Head to Head Contrast: ImmunoGen (IMGN) vs. Ohr Pharmaceuticals (OHRP)Head to Head Contrast: ImmunoGen (IMGN) vs. Ohr Pharmaceuticals (OHRP)
www.americanbankingnews.com - January 9 at 9:38 AM
Zacks: Ohr Pharmaceuticals, Inc. (OHRP) Given Consensus Recommendation of "Strong Buy" by BrokeragesZacks: Ohr Pharmaceuticals, Inc. (OHRP) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 6 at 5:18 AM
Ohr Pharmaceuticals (OHRP) Stock Rating Lowered by ValuEngineOhr Pharmaceuticals (OHRP) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - January 5 at 11:22 PM
Ohr Pharmaceutical (OHRP) Data from MAKO Study in Wet-AMD Did Not Meet Primary Efficacy EndpointOhr Pharmaceutical (OHRP) Data from MAKO Study in Wet-AMD Did Not Meet Primary Efficacy Endpoint
www.streetinsider.com - January 5 at 4:16 PM
Ohr Pharmaceutical (OHRP) Reports Efficacy Results from the MAKO Study in Wet-AMDOhr Pharmaceutical (OHRP) Reports Efficacy Results from the MAKO Study in Wet-AMD
www.streetinsider.com - January 5 at 10:35 AM
Here’s Why OHR Pharmaceutical Inc (OHRP) Shares Are Collapsing 80% TodayHere’s Why OHR Pharmaceutical Inc (OHRP) Shares Are Collapsing 80% Today
finance.yahoo.com - January 5 at 10:35 AM
Ohr Pharmaceuticals (OHRP) Downgraded by Roth Capital to "Neutral"Ohr Pharmaceuticals (OHRP) Downgraded by Roth Capital to "Neutral"
www.americanbankingnews.com - January 5 at 9:38 AM
Ohr Pharmaceuticals, Inc. (OHRP) Short Interest UpdateOhr Pharmaceuticals, Inc. (OHRP) Short Interest Update
www.americanbankingnews.com - December 30 at 2:00 AM
 Ohr Pharmaceuticals, Inc. (OHRP) Given Average Recommendation of "Strong Buy" by Analysts Ohr Pharmaceuticals, Inc. (OHRP) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - December 22 at 11:28 AM
Zacks: Analysts Set $7.00 Target Price for Ohr Pharmaceuticals, Inc. (OHRP)Zacks: Analysts Set $7.00 Target Price for Ohr Pharmaceuticals, Inc. (OHRP)
www.americanbankingnews.com - December 17 at 1:30 AM
-$0.08 Earnings Per Share Expected for Ohr Pharmaceuticals, Inc. (OHRP) This Quarter-$0.08 Earnings Per Share Expected for Ohr Pharmaceuticals, Inc. (OHRP) This Quarter
www.americanbankingnews.com - December 15 at 3:30 PM
Ohr Pharmaceutical Reports Fiscal Year 2017 Financial Results - GlobeNewswire (press release)Ohr Pharmaceutical Reports Fiscal Year 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - December 15 at 10:51 AM
Ohr Pharmaceuticals (OHRP) Scheduled to Post Earnings on WednesdayOhr Pharmaceuticals (OHRP) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - December 13 at 1:28 AM
Abeona Therapeutics (ABEO) vs. Ohr Pharmaceuticals (OHRP) Head-To-Head ContrastAbeona Therapeutics (ABEO) vs. Ohr Pharmaceuticals (OHRP) Head-To-Head Contrast
www.americanbankingnews.com - December 5 at 3:32 AM
Ohr Pharmaceuticals (OHRP) Lifted to "Sell" at ValuEngineOhr Pharmaceuticals (OHRP) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - December 2 at 10:36 PM
Ohr Pharmaceuticals, Inc. (OHRP) Research Coverage Started at Roth CapitalOhr Pharmaceuticals, Inc. (OHRP) Research Coverage Started at Roth Capital
www.americanbankingnews.com - November 27 at 10:10 AM
Zacks: Analysts Set $5.00 Price Target for Ohr Pharmaceuticals, Inc. (OHRP)Zacks: Analysts Set $5.00 Price Target for Ohr Pharmaceuticals, Inc. (OHRP)
www.americanbankingnews.com - November 26 at 3:18 PM
Financial Contrast: Soligenix (SNGX) and Ohr Pharmaceuticals (OHRP)Financial Contrast: Soligenix (SNGX) and Ohr Pharmaceuticals (OHRP)
www.americanbankingnews.com - October 23 at 6:30 PM
Ohr Pharmaceuticals, Inc. (OHRP) Downgraded by Zacks Investment Research to HoldOhr Pharmaceuticals, Inc. (OHRP) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - October 21 at 11:16 PM
Ohr Pharmaceuticals, Inc. (OHRP) Lowered to Hold at Zacks Investment ResearchOhr Pharmaceuticals, Inc. (OHRP) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 16 at 12:14 AM
Ohr Pharmaceutical to Present at the Dawson James 3rd Annual Small Cap Growth ConferenceOhr Pharmaceutical to Present at the Dawson James 3rd Annual Small Cap Growth Conference
finance.yahoo.com - October 12 at 7:51 AM
 Analysts Anticipate Ohr Pharmaceuticals, Inc. (OHRP) to Post -$0.07 Earnings Per Share Analysts Anticipate Ohr Pharmaceuticals, Inc. (OHRP) to Post -$0.07 Earnings Per Share
www.americanbankingnews.com - October 1 at 8:24 AM
Ohr Pharmaceuticals, Inc. (OHRP) Sees Large Drop in Short InterestOhr Pharmaceuticals, Inc. (OHRP) Sees Large Drop in Short Interest
www.americanbankingnews.com - September 30 at 3:26 AM
Ohr Pharmaceuticals (OHRP) and Its Rivals Financial ReviewOhr Pharmaceuticals (OHRP) and Its Rivals Financial Review
www.americanbankingnews.com - September 27 at 12:06 PM
Comparing Senesco Technologies (SVON) & Ohr Pharmaceuticals (OHRP)Comparing Senesco Technologies (SVON) & Ohr Pharmaceuticals (OHRP)
www.americanbankingnews.com - September 24 at 8:12 PM
Ohr Pharmaceuticals (OHRP) & Its Competitors Head to Head AnalysisOhr Pharmaceuticals (OHRP) & Its Competitors Head to Head Analysis
www.americanbankingnews.com - September 20 at 6:08 PM
Financial Comparison: Ohr Pharmaceuticals (OHRP) and Its PeersFinancial Comparison: Ohr Pharmaceuticals (OHRP) and Its Peers
www.americanbankingnews.com - September 15 at 9:02 AM
What Is Ohr Pharmaceutical Inc’s (OHRP) Share Price Doing?What Is Ohr Pharmaceutical Inc’s (OHRP) Share Price Doing?
finance.yahoo.com - September 15 at 7:09 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of ... - Business Wire (press release)SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of ... - Business Wire (press release)
www.businesswire.com - September 13 at 7:23 AM
 Brokerages Anticipate Ohr Pharmaceuticals, Inc. (OHRP) to Post -$0.07 Earnings Per Share Brokerages Anticipate Ohr Pharmaceuticals, Inc. (OHRP) to Post -$0.07 Earnings Per Share
www.americanbankingnews.com - September 12 at 12:26 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ohr Pharmaceutical, Inc.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Ohr Pharmaceutical, Inc.
finance.yahoo.com - September 12 at 8:12 AM
Reviewing Ohr Pharmaceuticals (OHRP) & its PeersReviewing Ohr Pharmaceuticals (OHRP) & its Peers
www.americanbankingnews.com - September 11 at 6:24 PM
HC Wainwright Analysts Give Ohr Pharmaceuticals, Inc. (OHRP) a $10.00 Price TargetHC Wainwright Analysts Give Ohr Pharmaceuticals, Inc. (OHRP) a $10.00 Price Target
www.americanbankingnews.com - August 16 at 8:02 AM
Head to Head Comparison: Ohr Pharmaceuticals (NASDAQ:OHRP) & Aevi Genomic Medicine (GNMX)Head to Head Comparison: Ohr Pharmaceuticals (NASDAQ:OHRP) & Aevi Genomic Medicine (GNMX)
www.americanbankingnews.com - August 10 at 10:24 PM
Ohr Pharmaceuticals, Inc. (OHRP) Issues  Earnings Results, Beats Estimates By $0.18 EPSOhr Pharmaceuticals, Inc. (OHRP) Issues Earnings Results, Beats Estimates By $0.18 EPS
www.americanbankingnews.com - August 9 at 5:22 PM
OHR reports 3Q lossOHR reports 3Q loss
www.cnbc.com - August 9 at 6:05 AM
OHR reports 3Q lossOHR reports 3Q loss
www.cnbc.com - August 9 at 6:05 AM
Ohr Pharmaceutical Announces Fiscal Third Quarter 2017 EarningsOhr Pharmaceutical Announces Fiscal Third Quarter 2017 Earnings
finance.yahoo.com - August 9 at 6:05 AM

SEC Filings

OHR Pharmaceutical (NASDAQ:OHRP) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

OHR Pharmaceutical (NASDAQ:OHRP) Income Statement, Balance Sheet and Cash Flow Statement

Chart

OHR Pharmaceutical (NASDAQ OHRP) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.